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sessions, For each strategy, the associated compliance was estimated using 
survival curVes at 12, 24, and 52 weeks nnd tested statistically using the log 
rank test, A cox proportional hazards model was used to estimate the relative 
risk of compllgnca for each interval. Median time of follow up was 24 weeks 
for ST1 and 20 weeks for ST2, Clinical baselines characteristics were similar 
in both study groups. By univerlate analysis, the absonoa of previous smoking 
(p < 0,05), and the strategy evaluated (p' ~,P91) were the only predictors 
of compliance, The compliance curves were significantly different between 
both strategies (log rank tes t ,  0,001). The only Independent predictor of 
compliance was the strategy used. wlth the ST2 showing a significantly bettor 
compliance than ST1, Relative rlsk at 12 weeks RR = 2,3 [1,8. 2,9]; at 24 
weeks, RR ,. 2,95 [2,3, 3,7] and at 52 waeke, RR.  4,25 [3,2, 5,8], 
Conclusion: This study 8hews that the sfrategy with a eomblnntlon of 
multiple interventions to Increase patient commitment ~lnd Involvement In a 
variety of activities, significantly Improved the compllnnco to a rehabilitation 
program. This Is ef utmost Importance since et least three months tn a 
program 19 the minimum ttmo roqttlrod to achieve a ellnlcgl Impnot. 
• Anti.Inflammatory Effect Associated With 
Ttlglvcerlde Reduction 
F, Tomesslnl, C, Prl~tlpino, E,V, Scnbhla. MN Do Luon, S, Bnmnl, 
D, 8cribane, F, Ginnotti, W, van do Greet. A Mnnori, T, Pillage, F, Andreotti, 
Cafhot~c Uewer, qtty, Rome, Italy 
Dl~ltpldomla, Inflammation and impaired tlbrinolysis Increase the ask tOT 
coronary event9 and dnatl~, Lipid.lowering IlnS boon lound to reduce this 
risk, In ,'t randomized, do~blo-bllnd, cross-over stL~dy o! hypetlriglyceridemic 
men (n ,~ 12.394]4 yts; 6 with stable Ischomlc I~eart disease), we investigated 
whether lipid.lowQring influenced C.reactlve protein (CRP) end baseline and 
post.exer¢l,'~o llbtin0ty~ls, k morning fnst~og bleed sample was taken pro- 
end post-maximal exemlse (known to stimulate fibrlnolysis) before and after 
2-months' treatment with gomflbmzil (G: 600 mg ~ 2/d) or placebo (P), 
for measummontn of Iiplds, CRP, tissue.type plnsmlnngon activator (t.PA, 
ug/L), plasmln-antlplasmln (PAP. ug/L) and plngmtnogen activator inhibitor-1 
(PAl-l), 
Ae expected, during P. patients with IHD, vs those without, had higher 
CRP (median 4,5 va 1,1 rag/L, p = 0,006) and PAl,1 (median 86 vs 44 ug/L 
p = 0,006). Moreover, CRP and PAIq were strongly rotated (r = 0,84. p = 
0.0006). A signitlcant, similar Increase of f-PA antigen was observed tn all 
study phases after oxemiso (post-) compared with before (pro,) (p .  0,0003) 
Altar G, baseline triglyceridos (TG, mgldL) and CRP wore both significantly 
reduced, and PAP concentrations wore increased: 
TG' CRP PAP t.PA pro- t-PA post- 
P~acobo 4£.s ~ P,? ~ 4 164 12 17 
GomfibroziI 266 ~ 51 1 4 245 12 18 
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Our data suggest that TG reduction in hypertrigtyceridemic men has both 
anti-inflammatory and pro-fibrinotytic effects, This may explain, at least m 
part, the clinical benefits of lipid-lowering. 
•75• Grape Juice Inhibits Human ex Viva Platelet Aggregation While Orange and Grapefruit Juices 
do Not 
J.G. Keevil, H. Osmae, N, Mantel. JD. Felts. Cardiology Section. Unwersity 
of Wisconsin, Madison Wl. USA 
Background., Platolots contnbute to the progression of atherosclerosis and 
precipitate coroosry thrombosis leading to myocardial infarction (MI). Red 
wine and purple grape iuico (G J) contain flavonoids (Fs) with antioxidant and 
anti-platetet properties thought to reduce death from coronary artery disease 
(CAD). GJ prevents expenmental thrombos~s in monkey carotid and dog 
coronary arteries (Felts model). Orange juice (OJ} and grapefruit juice (GFJ) 
contain a different class of Fs than GJ (tlavones vs. Ilavonols). 
Methods: Ten healthy human subjects drank 5-7.5 ml/kg/day of GJ. OJ or 
GFJ daily for 7-10 days each in a three arm crossover design. Whole blood 
platelet aggregation (PA) studies were done at baseline and after each juice 
had been consumed. 
Results: Ddnking grape juice for one week inhibited the PA response to 
1 ~g/ml of collagen by 84% ~; 20% (p = 0.003). OJ and GFJ had no effect 
on PA. Platelet inhibition was still at full effect two days after stopping GJ 
consumption, but was gone in seven days. 
Conclusion: Drinking GJ daily for one week poteetly inhibited PA while 
OJ and GFJ had no effect. It appears that the flavonols in GJ. taken orally 
are more effective PA inhibitors than the flavones in OJ and GFJ. The GJ 
platelet inhibitory effect was stronger than a published standard for aspirin 
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suggnsting that GJ, t~ken daily, may be as effective as aspirin in doe;tensing 
risk of ML 
• Hoalth's Impact on Drinking Behavior: The 
Atherosclsroals Risk In Communities (ARIC) 
Study 
M L, Eigeobmdt, F,D, Fuchs, R,G. Hutchinson, I..,~, Chamblo~s, C,C, Paten. 
University el Misst~ssppi Medical Center, Jackson, MS, USA 
Baekgtollnd; It has been suggested ff~at the pufattvo protective effect el 
moderate alcohol consumption on cardiovascular disease is because of 
salf,selootien far drinking by those who am hoaffhier, 
Mc}thods" To test how a change in health affects drinking behavior, we 
studied 174 bl¢tck women, 2S2 black men, 2065 white women, and 1991 whdo 
mac ~rom fflO ARIC study who worn dnnkors at visit 1. who ha~d no htsfow 
at disease 0r, Voca~dtal infamtion, stroke, hyper!onslon, diabetes, ca~r ,  
or lung disease) at visit 1, and who reported dnnker status and disease 
status appmxlmatety 3 years later at visit 2. The ethnic/gender.specific, age- 
and income-adjusted odds of stopping drinking were modeled by logistic 
regression analyses for those who developed one or more of the diseases 
by visit 2 (n comparison to these who remained disease free. 
Results: In throe ethnic/gender strata, the development of disease was 
strongly associated with stopping dnnking, The odds ratios (95% CI) were as 
follows: Black men, OR = 2,9 (1.46--5,69); white men, OR = 1,6 (1.0B--237): 
white women OR = 1.8 (1,25-2.69); and black women, OR = 06  (0.21-1.68) 
Conclusion: Change in awareness of disease status is associated with a 
change in drinking behavior and should be considered when evaluating the 
cross-sectional association of alcohol and disease outcomes. 
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~ Total Hospital Cost for Coronary 
Revascu|ar|zatlon: Hasp|tat (UB92) and 
Professional (RBRVS) Components 
W.S. Weintraub. S Connolly. D. Canup, C. Deafen, S. Culler, E Beaker 
Emery Unit; Atlanta. GA. USA 
Total hospital cost of eorenaq., revascularization include hospital and protes- 
sional (Prof) components. Hospital cost is often determined from the hospital 
charges (UB92), reduced to cost by departmental cost to charge ratios. Prof 
costs are generally either not included or estimated tram Medicare reim- 
bursement for specific procedures, which will not cover all sen/ices provided 
during an episode of care (EOC). At Emery University there is centralized 
billing• permitting collection of all CPT codes for an EOC. CPT codes (and 
modifiers) may be related to ProI resource use by their relative value units 
(HVUs). RVUs include wurk and practice components which may be added to 
form total RVUs. RVUs for all services during an EOC are then ;.:mined and 
multiplied by the Medicare conversion factor to calculate Prot cost. Total cost 
of coronary revascularization was determined in 3,132 patients undergoing 
PTCA and 2,078 CABG in 1994 & 1995, in 1995 $: 
CABG 94 CABG 95 PTCA 94 PTCA 95 
Hospital Co~t $20.U6~ $16,333 $9.046 $6,908 
Work RVUs 47 42 20 17 
Total RVUs 109 100 52 46 
Prot Cost $4,358 $3.916 $2.071 $1.713 
Total Coz.t $24,355 $20,116 $11,072 $8.601 
All measures of resource use declined from 1994 to 1995. p ~ 0.0001. 
Ability to predict total cost from the Emery clinical database was modest 
unless length of stay (LOS) was included in the model: for CABG r2 = 0.16 
JACC I:ehnmr). ItJtJ,~ AltSTRA("I'.~- P-,t,:r IT.~A 
for clinical charactenstics (CO), r2 = 0.22 for CC + complications (COMP) 
and, r2 = 0.72 for CC + COMP + LOS; for PTCA r2 = 0,19 for CC, r2 = 0.49 
for CC + COMP and r2 = 066 lot CC + COMP + LOS, Iho sum el hosp¢ta| 
and total professional cost provide the best cost estvmato currently possible 
Whale cost is declining these data reveal still unexpiavnod variahon ~n cost 
~ D o  PTCA Mortality Outcomes Need to Be 
Rlsk-adluated? Results From the National 
Cilrdlovas©ular Network (NCN) 
ED. Petefson, D, Moore, LH  Muh!baier, ER  OeLong Duke Univ~r~i~: 
Durham. NC, USA 
BacAgreund: Increasing=y, hospitals' percufaneous, COrOnary infenrention 
(PTCA) me,rarity rotes are being compar~ aa ~t marker of quality. These 
comparisons, however, rarely adlust for differences in hospitals" casemix, 
Methods. Using. the NCN ~'~fobaso (n = 58,;'14 PTCA I~rformed at 19 
U,S, centora from 1/94 to 1/977, we compared hospitals' unadlusfed mortality 
ra+lkleg5 with those a~er n~k-ndtusfing the outcomes Ior t2 c/!nica! nsk factors 
(model C.inde~ = 0.815) 
Results: Overall NCN PTCA in-hosp+t~l mortahty rate was t 2%, varying 
from 0,5% tO 24% between hospitals. Below, we display the 19 hospitals 
ranked by their unadjusted and nsk-adl~sted mortality rates. 
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Hospitals' Rlsk-Ad|ustnd Morlallty Rank 
Hospital ranking shifted an average of 3.6 ranks (range 0--117 Spearman's 
coefficient between rankings was modest, 0.63. 
Cor~us~on. Sigeit~cant differences exist between a hospital's unadjusled 
and risk-adjusted PTCA mortality rankings. Thus, compansons of quality 
need to be based on ask-adjusted outcomes in order to be meaningful 
• Increasing Age Adds to the Costs of PTCA 
P.T. Vaitkus. Universd), Hospitals and Case Western Reserve University+ 
Clevelanct OH. USA 
Background. It has been recognized that elderly patients face increased 
ask of perculaneous coronary revasculanzation. We sought to determine d 
increasing age also impacts on the costs of PTCA. 
Methods: We examined cost data on 484 consecutdve PTCA pts over 6 
months. Raw cost data and risk-adlusted cost data were compared for pts 
aged T 70 vs. p~ . 70 
Results: Multivariate analysis identifiedthat PTCA for staole angina was 
associated with lower costs, whereas PTCA for acute MI, shock, and the 
number of lesions dilated were associated with increasing costs; these vari- 
ables were used to perform ask adjustment. Older pts were more likely to be 
female (53% vs 31%, p - 00001) and had more diseased coronaries (1.8 
vs 1.56, p = 0009) than young pts There were no differences in # of les~ons 
dilated, indication for PTCA, complication rates, clinical urgency, need for 
antecedent bepann or iv nitroglycerin, frequency el new .tevice usage, or 
AHA,'ACC lesion complexity. Costs for older pts ($9763".g8 .~: 7881.897 were 
significantly higher than for young p!s ($8341.78 .~ 5879.11; g = 0.036). A 
significant difference persisted after adlustment for baseline variables. Older 
pts had longer overall and post-PTCA lengths of stay (LOS). The trend for a 
longer pre-PTCA LOS for older pts did not reach stahstcial significance. 
Conclusion: Older pts have longer LOS and costs of PTCA. Efficienctes 
achieved tn at-large PTCA populations may not be transferrable to older pts. 
As current policies do not provide for increasing reimbursement for older 
patients, the aging of the population will translate into increased cost and 
falling profit margins for providers of PTCA services 
• Internal Validity of AMI Databases: A Comparison 
" -  of the NRMI-2 and CCP Databases 
NR Every, P Frederick, M Robinson C Maynard, L Bowlby, HV Barren 
Onvfstori of Cordto/o~y, Unltn~r$1ty of W~lsh~, on, SeaPJe, WA USA 
For patients with AMI, there ~m two large (~ffibaso~ which attempt to c~l~ 
tore pf characteriStiCs, freatnl~nt~ and outcomes, The Natiooa! Registry 0t 
Myocardial Infamtion (NRMb;~) is a voluntary indusfn/~poosored Roe, airy 
that folios on IocPI hespffa! pt identification aed chart abstraction while 
HCFA's Cooperative Cardiovascular Proje~t (CCP) is a govemment.spoo. 
soled database with centralized ca~o ascerlainmenf and validated chaff 
abstraction pr~e~,  In orOer to compare the two d~tabases, we ~lectecl 
Medicare.eligible pts from each database admitted to the same ho.~pitals 
during the same time pmiod in 1,087 hospitals (35,675 pta tn NRMb2 and 
42,703 pts in CCP), We then compared the two cohorts 
CCP (N ~ 42,703i NFIMI,2 (N, 35.875| P value 
Age (mean ~ SD) ?73 ;6 9 O 3r~t 
Gem'lef (% Mafel 494 503 O 0r.5 
White RaCe (%l 89 5 866 0001 
USe el '~r= |%) 14 8 15 6 0 e0t 
Cath (%) 32 B 33 3 0 156 
PTCA (%) 12.5 12 8 0 640 
CABG (%) ? 0 7 1 0420 
Hospital Monahty (%) 16 1 t97 O 001 
We then matched mdiwdual pts, and were able to identily 25,684 pt 
matches from each dataset In this pt-level comparison there was agreement 
in vanable classification m race 96%, gender I00%, age 99%, pnor AM188%, 
use of TTx 98%. cath 98%. and hospital mortality 99.4%. 
We conclude, that despite possible non..consecutNe case ascertainment, 
the hospital-based NRMI-2 compares favorably to the more centralized CCP 
database 
• Relationship of Clinical Variables to Hospital Cost 
for Coronary Interventions: A Unlvarlate and 
Multivariate Analysis 
RW Ltgon, F L. Mike,, JT  Dove, CL  Lucore Prame Cardiovascular 
Consultants, Ltd., Spnnglretd, I/heels. USA 
To determine the relationship of clinical vanables to hospital cost, we reviewed 
data on 2399 consecutwe hospktat discharges between 1/96 and 6~7 after 
coronary inlen~entions (DR'3 112) Baseline characlenstics el tl~e group 
included: age of 64.7 ~, 12.0 years. 64% males, 4.7% acute MI, 67%, stents. 
The ave.age hospital cost was $9499 and lenolh ot stay was 3.2 days 
Multiple stepwvse regression was used to develop a regresmon equatvon for 
predicting hospital cost (R;: = 050: p - 00017 
t,,,~an Hospffal Cos15 IUnlvarlato] Regression 
With iS) Without (St P ($1 Coeff+oenl ($l 
Acute M1 r 0680 944 l 
D~abetas 9962 9361 
MI 3a dny~, 10661 9126 
Muitlves~et CAO 10830 9049 
A~ • 70 9774 9341 
F~rn~te 9722 9372 
Stenr Procedure 10689 7116 
LVEF- 40°° 9499 9336 
Hx et CHF t1383. 9294 
Prior Inter~enhon 653~ 9879 
Abclxtmab use ~ q6;:50 8764 
2 no Iriterventron 1614,3 9290 
Co51 per each stem 
0 003 173R 68 
9004 46950 
o 001 1357 63 
0 oo I 548 52 
0018 498 66 
0 057 43914 
0001 202802 
0001 41707 
0001 182137 
0 001 42068 
ooor 118801 
0 001 647082 
1332 
Predicted cost = regression constant ($5243.43) z: appidcable regres+ 
sien coefficients. Thus. selected chnical vanables can be used to pn~dicl a 
significant proportion of the costs of hospvtalizatien for coronary intervention 
